Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02272543
Other study ID # PR-14047
Secondary ID
Status Completed
Phase Phase 1
First received October 21, 2014
Last updated September 21, 2017
Start date October 2014
Est. completion date December 2016

Study information

Verified date June 2016
Source International Centre for Diarrhoeal Disease Research, Bangladesh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Protein-energy malnutrition (PEM) including moderate acute malnutrition (MAM: weight-for-height z-score <-2 to -3, or mid upper arm circumference (MUAC) 115 to < 125 mm) is a major cause of morbidity and mortality in under-5 children of developing/low-income countries. Approximately 14.6% of all under-5 mortality worldwide is attributed to MAM. Prevalence of MAM among under-5 children in Bangladesh is ~12% (~1.7 million). Providing a diet containing adequate nutrients is the mainstay of treatment of children with MAM. Dietary protein is mostly derived from vegetable sources for the middle and low income population among whom the prevalence of MAM and other forms of PEM is high. It is now possible to process fish into fish peptides with longer shelf-life without refrigerator, known as 'fish Surimi' and consumed by different categories of people who need more well-balanced protein; this could be an attractive alternative to supply fish protein in the diet of children in low-income countries like Bangladesh.

Fish Surimi peptide is broken down from white fish meat using plant-derived enzyme and the ingredient is just fish meat consisted of 20 different kinds of amino acids including nine essential amino acids. In human studies it is found to help lowering blood lipids, glucose, IgE, hypertension, and increasing serum albumin and total protein, and bone density.

The present study is designed to assess acceptability and efficacy of 'fish Surimi' in 2-5 years old children suffering from MAM. A pilot study with two phases: to assess the i) acceptability with a small convenience sample (N=30) (phase 1); and ii) efficacy (rate of weight gain) of this fish peptide in a small convenience sample (N=70: 35 intervention 35 control) (phase 2) is proposed.

Acceptability trial (first phase): The investigators will conduct this study in the study ward of Dhaka Hospital of icddr,b. For each child the study will be for two days: i.e. direct observation of food intake of two lunches and two suppers. In a randomly manner and cross over design, an individual child will be offered 5g of fish Surimi during lunch and 5g during supper in one day or the same meal without any fish peptide on the other day in a blinded manner. The investigators will observe the completeness and eagerness of eating and any possible side effect (e.g. allergy, vomiting, diarrhea etc.) over these two days.

Pilot efficacy trial (second phase): The investigators will conduct a pilot trial to assess the efficacy (mainly on child weight gain) of fish Surimi given at home with various foods/meals in 2-5 years old children with MAM will be conducted in Dhaka City of Bangladesh. Children will be enrolled from the Dhaka Hospital of icddr,b after improvement of any acute illness. The intervention group will receive (as take home supplementation) two-week's ration of fish Surimi (@10g/day in two doses i.e. 5g + 5g each in airtight packet), which will be served twice daily mixed with family diet. The control group will not be provided any supplements but the parents will be given dietary advice to provide nutritious food to the child in adequate amounts, and children of both groups will receive micronutrient sprinkle. The child's guardian will be supplied with fish Surimi during initial discharge from icddr,b hospital and requested to come for a fortnightly follow up at the nutrition follow-up unit (NFU) of icddr,b. During each follow-up visit the study research assistant/health worker will do the anthropometry, collect morbidity history since the last visit/follow up and dietary history will also be taken to find out how the child is doing along with the fish Surimi intake. Treatment of any illness will be provided as per standard method by on duty physician of the Dhaka Hospital of icddr,b. The ration for next two weeks will be provided and in such way each child will be followed for ~ 3 months over six NFU-follow-up visits. To reduce the possible drop-out the both-way transportation cost (~ 150 to 250 taka) during each follow-up visit will be reimbursed to the guardians. In the middle of the two scheduled follow-up days the research assistant will call the family by cell phone to monitor the child's feeding and morbidity status. Approximately 5ml blood will be collected from the ante-cubital vein of the children for biochemical test on enrolment and at the end of 3 months and will be analyzed for haemoglobin (Hb), c-reactive protein, zinc, ferritin, albumin, total protein, and IgE. During the blood drawing days each child will be given a toy (take home).


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years to 5 Years
Eligibility Inclusion Criteria:

- Signed informed consent from guardian

- Ages 2 to 5 years

- WHZ<-2 to -3or (MUAC) 115 to < 125 mm without any edema

- Parent/guardian planning to stay in the same area for 3 to 4 months (for smooth follow up purpose)

Exclusion Criteria:

- WHZ = -3 z-scores or presence of bilateral pedal edema

- History of allergy to any fish product

- Anorexia, jaundice or chronic disease or any serious illness warranting hospital referral

- Any congenital anomaly

- Concurrent participation in another clinical trial with intervention to the child

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fish surimi peptide


Locations

Country Name City State
Bangladesh icddr,b Dhaka Hospital Dhaka

Sponsors (2)

Lead Sponsor Collaborator
International Centre for Diarrhoeal Disease Research, Bangladesh Suzuhiro Kamaboko Co., Ltd.,Japan

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary outcome measures: Weight gain after serving the test diet for 12 weeks: changes in body weight during the study period will be measured and 'weight-for-height Z-score 'will be calculated. 12weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06038071 - Family Mid-Upper Arm Circumference (MUAC) Follow-up After Recovery From Acute Malnutrition (MODAM-fMUAC) N/A
Not yet recruiting NCT06056089 - Modified Dosage for Moderate Acute Malnutrition (MODAM-MAM) N/A
Completed NCT02571764 - Supplementary Food for Moderate Acute Malnutrition in Children N/A
Recruiting NCT06002438 - Eggs for Gut Health N/A
Not yet recruiting NCT06045104 - Alternative Feeding Regimen on Recovery of Children Aged 6-59 Months With Moderate Acute Malnutrition in Bangladesh. N/A
Recruiting NCT06214897 - Choline to Prevent SAM in Children With MAM N/A
Completed NCT03751475 - Optimizing Acute Malnutrition Management in Children Aged 6 to 59 Months in Democratic Republic of Congo N/A
Completed NCT01115647 - Treating Moderate Malnutrition in 6-24 Months Old Children N/A
Completed NCT03474276 - Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old Phase 3
Completed NCT01898871 - Effectiveness of Nutritional Products to Treat Moderate Acute Malnutrition Phase 2
Completed NCT01147198 - Ready to Use Supplementary Food in Moderate Childhood Malnutrition N/A
Not yet recruiting NCT06305442 - Microbiota Directed Food for Children With Moderate Acute Malnutrition N/A
Terminated NCT03087097 - Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition Phase 1
Completed NCT03146897 - Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition N/A